Mounjaro vs Zepbound: what is actually different

What this guide covers

Mounjaro and Zepbound are the same molecule, tirzepatide, sold under two names for two FDA-approved uses. Here is why both exist, how the dosing compares, and why the label on the box can decide what your insurance pays. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer. Mounjaro and Zepbound contain exactly the same active drug: tirzepatide, a once-weekly injection that activates two incretin receptors, GIP and GLP-1. The difference is the label. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management, and also for moderate-to-severe obstructive sleep apnea in adults with obesity. Same molecule, same doses, same manufacturer (Lilly), different approved uses. Which one you are prescribed usually comes down to your diagnosis and what your insurance will cover, not to any difference in the drug itself.
• Why one drug has two names. Drug companies apply to the FDA for one indication at a time, and each approved use gets marketed under its own brand. Lilly first won approval for tirzepatide in type 2 diabetes in 2022, and that product is Mounjaro. When the SURMOUNT trials showed large weight-loss effects in people without diabetes, Lilly sought a separate approval for chronic weight management, granted in late 2023, and launched the same molecule as Zepbound. Novo Nordisk did the same thing with semaglutide, which is why Ozempic and Wegovy both exist. It is a regulatory and insurance structure, not a scientific one.
• The dosing is identical. Both products start at 2.5 mg once weekly for four weeks, then step up in 2.5 mg increments as tolerated, with a maximum of 15 mg weekly. The full titration calendar is in each product's FDA prescribing information, and we walk through it in our dosing schedule guide. Maintenance doses differ by person, not by brand: the right dose is the lowest one that controls what it was prescribed for, and prescribers routinely hold or slow the climb when side effects are rough. There is no strength available in one brand that is missing from the other in the pen form, though Zepbound is also sold in single-dose vials through Lilly's self-pay channel.
• Side effects: the same list. Because the molecule is the same, the side-effect profile is the same: nausea, diarrhea, constipation, vomiting, and reduced appetite lead both labels, heaviest in the weeks after a dose increase, and both carry the same boxed warning about thyroid C-cell tumors seen in rodents. Fatigue, burping, and injection-site reactions show up on both labels too. If you tolerate one, you would be expected to tolerate the other at the same dose, and the management playbook for nausea, constipation, and diarrhea is identical.
• What the trials showed, briefly. Mounjaro's diabetes approval rests on the SURPASS program, where tirzepatide lowered A1C more than comparators including semaglutide 1 mg (SURPASS-2). Zepbound's weight approval rests on the SURMOUNT program, where adults with obesity lost around a fifth of body weight on average at the higher doses over 72 weeks (SURMOUNT-1), and the head-to-head SURMOUNT-5 trial found more average weight loss on tirzepatide than on semaglutide 2.4 mg. The OSA approval came from the SURMOUNT-OSA trials, where tirzepatide reduced breathing interruptions during sleep. All of that is the same molecule you get under either name.

Frequently asked questions